US & Europe Opioid Market to Gain Traction Going Forward, Says MP Advisors in Its Discounted Report Available at MarketPublishers.com16 Jan 2017 • by Natalie Aster
LONDON – There were nearly 18,893 deaths associated with the prescription of opioids in the USA as of 2014, indicating an upsurge of 16% from 2013.
Over 6 extended-release (ER) formulations with abuse-deterrent (AD) properties on their labeling, are approved in the past couple of years Hysingla ER, MorphaBond ER, Xtampza ER, Embeda ER, Oxaydo and Targiniq ER, and are projected to provide dramatic improvements over current formulations for AD purposes. But they have certain limitation for inhibiting abuse primarily through peroral administration – taking a set of intact capsules or tablets. In spite of this, ER AD formulations control opioids abuse to a certain degree, ER opioids has strong possibility of abuse, its AD formulation add enormous value to create Abuse Deterrent Era in the offing.
More than 20 ADF opioids are presently in the pipeline, among which 8 are of morphine, 6 are of hydrocodone and 6 are of oxycodone-based ADF formulations.
The US opioids market size stands at USD 8 billion, with ER formulations contributing 50% of the overall market. The opioid market across the USA and Europe is projected to gain traction in the years to come, driven by ADF ER formulations and its generic drug versions and novel NCEs targeting opioid receptors.
Discounted research report “Pain Management- New Discoveries and Treatment Options in Abuse Deterrent Era” created by MP Advisors provides an all-round, detailed analysis on the market. The study gives true insights into the management of pain, gives information on the FDA schedule for controlled substances and benefits of schedule III over II; FDA perspective on AD formulations (opioids); approved AD formulations by FDA - development, labeling claims, technology and present-day prescription trends. It sheds light on a range of novel delivery technologies exploited in formulating AD product, technologies used in improving patient compliances, emerging new mechanisms and drugs in late-stage clinical development in neuropathic pain management. The study limelights the competitive landscape of the market and offers granular profiles of the most prominent players.
More insightful research studies by the publisher can be found at MP Advisors page.